Resources

The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments: Key Findings and Implications


DownloadThe Evolution of Biomarker Use in Clinical Trials for Cancer Treatments: Key Findings and Implications, a study conducted by L.E.K. Consulting and published by PMC, shows that the biopharmaceutical industry is deeply invested in developing immunotherapies and other cancer treatments that are designed to influence the activity of specific molecules involved in the growth of cancerous cells. The study underlines the importance of aligning patients, policymakers, and representatives from all sectors of the health care ecosystem on reimbursement policies that will ensure sustainable access to biomarker-based cancer therapies, some of which are associated with dramatic clinical benefits but increased manufacturing costs based on the need to develop a personalized therapy for each patient by genetically re-engineering the patient’s own cells.

Join Today

PMC members shape and advance the future of personalized medicine.
Join Today